Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Surveillance van COVID-19, griep en andere luchtweginfecties winter 2021/2022
sep 2022 | Pneumonie, Tuberculose, Virale infecties